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Abstract
Urinary tract infections (UTIs) are the commonest human bacterial infections and are 
responsible for substantial morbidity and mortality, resulting in increased healthcare 
costs. Most UTIs are caused by specialized Escherichia coli (E. coli) strains referred to as 
uropathogenic E. coli (UPEC). UPEC possess a variety of virulence factors (VFs), which 
the organism uses to attach, invade, and injure the host. These VFs include adhesins, 
toxins, iron acquisition factors, lipopolysacharide capsules, and other invasins. Most 
studies on UTI pathogenesis have targeted VFs. The source of UPEC is the host’s fecal 
flora. According to the pathogenicity theory, UPEC strains with special VFs move from 
the host’s fecal flora to the urogenital tract and cause UTI. However, another theory 
states that the numerically abundant strain is responsible for UTI. Effective UTI man-
agement is hampered by the recent rise in antibiotic resistance, specifically, the recent 
emergence of multidrug-resistant E. coli sequence type 131. The distribution of VFs and 
other bacterial characteristics among different patient groups and UTI syndromes, is cru-
cial understanding UTI pathogenesis, which would guide clinical decision making. For 
ST131 clonal group, further epidemiological studies are needed to clarify transmission 
pathways, risk factors for spread, and reservoirs, so that effective control measures can 
be devised.
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1. Introduction
Urinary tract infections (UTIs) are an important medical problem, being the second most com-
mon bacterial infection of humans after respiratory tract infection. They are often recurrent, 
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frequently difficult to treat, and can cause parenchymal damage to the kidney, leading to renal 
insufficiency and further complications [1–3]. UTIs impose a substantial burden on society 
and the health care system in relation to diagnosis, management, lost productivity, morbidity, 
and sometimes death [4–6]. Furthermore, increasing resistance to therapeutically important 
antimicrobial agents and the recent emergence of the virulent and multidrug-resistant ST131 
clonal group have made UTI management progressively more costly and challenging [7, 8]. 
Several studies suggest that a greater array of VFs is generally needed to cause more invasive 
UTIs, although the extent appears to differ according to age and gender. Thus, further  studies 
targeting VFs, which have been proposed as the best target for vaccine development, are 
needed. A better understanding of UTI pathogenesis, especially for the most common cause 
of UTI, namely Escherichia coli, is crucial for treatment and prevention of UTIs.
2. Etiology of UTI
UTIs are mainly caused by bacteria, although fungi and some viruses have also been impli-
cated. Among bacteria, Gram-negative bacteria of the Enterobacteriaceae family,  including 
E. coli, Klebsiella, Enterobacter, Proteus species, etc., are mostly involved. However, some 
Gram-positive organisms, principally Staphylococcus aureus, Staphylococcus saprophyticus and 
Streptococcus agalactiae, also play a role especially among young women. E. coli is the dominant 
causative agent in all patient groups, causing 80–90% of all UTIs [5]. Consequently, E. coli 
serves as a model pathogen for studying UTI pathogenesis.
Escherichia coli is a normal constituent of the intestinal microbiota of humans and animals [9, 
10]. The distinctive E. coli strains that cause most UTIs have been designated uropathogenic 
E. coli (UPEC). They possess diverse virulence-associated factors (VFs) that assist them in 
 attaching to, invading, and injuring the host, and include adhesins, toxins, siderophores, 
protective polysaccharide coatings, invasins, and serum resistance-associated proteins. 
The presence and numbers of such VFs predicts in vivo virulence [11].
3. Epidemiology and risk factors for E. coli UTI
Overall, UTI is more prevalent among females than males, attributable to the close proxim-
ity of the urogenital tract to the anus in females, the greater length of the male urethra, and 
the antibacterial activity of prostatic fluid in men [12, 13]. Functional, hormonal, and ana-
tomical changes that occur during pregnancy predispose pregnant women to UTI [14]. UTI 
during pregnancy can result in devastating maternal and neonatal complications,  including 
maternal sepsis, preterm labor, and premature delivery [14]. Thirty percent of patients with 
untreated asymptomatic bacteriuria (ASB) develop symptomatic cystitis and up to 50% 
develop pyelonephritis [13]. ASB is also associated with intrauterine growth retardation and 
low-birth-weight infants [13]. Up to 27% of preterm births have been associated with UTI in 
pregnancy [14].
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Among bacterial infections in children, UTI ranks highly, even outnumbering bacterial menin-
gitis, pneumonia, and bacteremia [15]. About 1% of infants < 3 months old develop UTI, with 
more males affected than females. Proper and urgent UTI management is crucial in children as 
an estimated 10–15% of children with UTI will develop permanent kidney damage, leading to 
other chronic diseases such as hypertension and renal insufficiency [16, 17].
The propensity of UTIs to recur, often within a few weeks or months after an initial acute 
infection, is a problem in UTI management. Approximately 20–30% of women will have a 
recurrent bladder infection within 6 months after an initial episode, and an additional 3% will 
experience a third infection [18, 19].
4. E. coli UTI pathogenesis
UTI pathogenesis is a complex process that is influenced by various host biological and 
behavioral factors, and by properties of the infecting pathogen, including VFs. This presents 
a challenge in epidemiological studies regarding the role of specific VFs in UTI pathogenesis 
because of the confounding effect of host factors.
In most noncompromised individuals, the urinary tract is normally sterile, and the entry of 
exogenous microorganisms is prevented by urine flow, secreted and tissue-associated anti-
bacterial factors, and the bactericidal activities of effector immune cells. In most cases, the 
host fecal flora is the source of the infecting E. coli strain, and spreads via the perineal,  vaginal, 
and periurethral areas to the lower urinary tract (i.e., urethra and bladder) where they may 
establish colonization [20]. Two hypotheses have been proposed to explain the movement of 
the organism from the fecal flora to the urinary tract. The prevalence hypothesis holds that the 
numerically most prevalent E. coli clones in the feces will be involved, whilst the  pathogenicity 
theory holds that E. coli strains with enhanced virulence potential will be selected [20]. These 
two mechanisms may not be mutually exclusive, but instead may jointly contribute to UTI 
pathogenesis [21].
Although the host’s fecal flora is the major source of the E. coli infecting strain, other proximal 
external reservoirs of the organism have been described. Community outbreaks of UTI have 
been reported [22–24], but without any evidence of person-to-person transmission. Foods and 
water have been proposed as possible vehicles of such outbreaks [22–24]. Specifically, exten-
sive molecular similarities between E. coli from retail meat products and healthy or infected 
humans have been described [22]. Within-household spread of E. coli among co-habitating 
humans and their pets, including between sexual partners, have been confirmed [4, 10, 11]. 
The VFs of the invading bacteria and the host’s defense mechanisms determine the outcome 
of the infection [25]. A variety of host factors, such as age, gender, pregnancy, or immunologi-
cal status, may predispose to UTI and allow less virulent pathogens to cause the disease [20]. 
If the infection is confined to the lower urinary tract, with symptoms such as dysuria and 
frequency of urination, the infection is referred to as acute cystitis. If the infection spreads to 
the upper urinary tract with symptoms such as flank pain, fever, and malaise, the infection is 
defined as an acute pyelonephritis.
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5. Uropathogenic E. coli (UPEC) and virulence factors (VFs)
Virulence refers to the ability of an organism to cause disease, and is a function of the presence 
of distinct accessory traits, referred to as virulence factors (VFs). VFs are specific properties 
that enable organisms to overcome host defenses and cause disease [26]. However, although 
several VFs have been identified in UPEC, experimental and epidemiological data have 
shown that none uniquely defines these pathogens.
UPEC VFs are grouped by functional categories as adhesins, toxins, iron acquisition systems, 
and protectins. VFs are encoded by genes located on chromosomes or plasmids, with some 
being exclusively chromosomal (e.g., pap and hly), others exclusively or principally plas-
mid-associated, e.g., iss and traT, and some either chromosomal or plasmid-associated (afa). 
Consequently, VFs may be vertically or horizontally transmitted, further contributing to the 
complexity of understanding the role played by specific VF genes in UTI pathogenesis.
6. Structure of adhesins
Adhesins, which appear as hair-like fibers called fimbriae (or pili), facilitate the colonization 
with E. coli in the urinary tract by attaching to host epithelial cells. This attachment promotes 
the persistence of the organism in the bladder, and serves as a reservoir for ascending infection 
in the urinary tract [27].
Various adhesins have been identified and are classified mainly according to receptor 
specificity, with some being mannose resistant and others sensitive. P fimbriae (or pili), the 
best-described group of mannose-resistant adhesins of UPEC, are so named because they 
specifically bind to the Gal(α1–4) Gal disaccharide galabiose, which is an antigen within 
the human P blood group system [26]. Different components of the P fimbriae have been 
described, including four different units that are at the tip of the fibrillum, including PapG, 
PapE, PapF, and PapK [28–30]. These fimbrial proteins and other accessory proteins are 
encoded by a chromosomal multicistronic gene cluster termed pap (pilus associated with 
pyelonephritis), which can be carried on large chromosomal insertions called pathogenicity 
associated islands (PAIs) [31].
Actual attachment of the organism to host epithelial cells is effected through PapG by recogni-
tion of glycolipid receptors expressed on host kidney cells and red blood cells [32]. Three vari-
ants of PapG, encoded by distinct alleles of the corresponding gene, pap, have been identified, 
namely PapGI, PapGII, and PapGIII [32–34]. Most studies indicate that allele II is the main 
PapG variant in E. coli bacteremia (regardless of primary source), acute pyelonephritis, and 
acute prostatitis, whilst allele III predominates in acute cystitis [33, 9]. Other studies found 
statistically significant associations between allele III and several compromising host condi-
tions, such as urinary anatomical abnormalities, diabetes [33, 35].
Type 1 fimbriae are the commonest adhesive organelles of E. coli. They mediate adhesion of 
the organism to secreted and cell-bound mannosylated glycoproteins and exhibit mannose 
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sensitive hemagglutination of guinea pig erythrocytes [36]. The ubiquitous distribution of 
these fimbriae in E. coli makes it difficult to show an association with UTI outside an experi-
mental setting. However, type 1 fimbriae exhibit several different phenotypes due to allelic 
variation of the gene for the lectin subunit, fimH, and these phenotypes have been shown to be 
distributed differentially among fecal and UTI isolates [37–39]. Type 1 fimbriae are encoded 
by a chromosomal fim gene cluster that contains genes for a structural subunit, an adhesin, 
several accessory proteins, and regulatory proteins (fimACDFGH) [30, 39].
Phase variation controls the expression of type 1 fimbriae by site specific recombination. A 314-bp 
phase-variable invertible element, that contains the promoter, controls the transcription of 
the fimbrial genes fimACDFGH. The promoter drives the expression of type 1  fimbriae when 
the switch is in the ON orientation but not when it is in the OFF orientation [40]. It has been 
shown that the expression of type 1 fimbriae coordinately affects the expression of P  fimbriae 
in an inverse manner, providing evidence of a direct communication between genes related 
to pathogenesis [41, 42].
Although most studies have confirmed that type 1 fimbriae are particularly important in blad-
der colonization [43, 44], the proportions of UPEC strains from urine and feces expressing 
type 1 fimbriae appear to be similar [26], ranging from a high of 71% among isolates from 
cystitis patients to a low of 58% among those from patients with ASB, with fecal strains in the 
mid-range at 60% [26]. However, in contrast, the level of expression of type 1 fimbriae among 
UPEC blood isolates (81%) is significantly different from that of fecal strains [45, 46].
Another adhesin family is the Afa/Dr family, which consists of adhesins that include the 
 uropathogen-associated fimbrial adhesin Dr, along with other nonfimbrial adhesins,  including 
Afa-1, Afa-2, Afa-3, Afa 4, NFu1, and Dr-11. These adhesins have a different structure from 
other E. coli fimbrial adhesins in that they appear as fine mesh, a coil-like structure or as a 
filamentous capsule coating on the cell surface [45, 47, 48]. Epidemiological studies show that 
E. coli strains that express adhesins of the Afa/Dr family are involved in 25–50% of cases of 
cystitis in children, and 30% of cases of pyelonephritis in pregnant women [49]. Moreover, 
E. coli strains expressing Dr adhesins have been associated with a two-fold increase in the risk 
of a second UTI. It has also been shown that UPEC encoding the Dr adhesin could survive for 
more than 1 year within renal tissue [49, 50]. These findings suggest a possible role for Dr/Afa 
adhesins in recurrent or chronic UTI.
Finally, the closely-related S fimbriae and F1C (fimbriae of serotype 1C), so named because 
of their binding specificity for terminal sialyl-galactoside residues, mediate X-type mannose 
resistant hemagglutination of human erythrocytes [51–53]. They agglutinate human and 
bovine red cells [54, 55]. S fimbriae have a similar, but less well defined, structure to both type 1 
and P fimbriae. Just like type 1 and P fimbriae, expression of S fimbriae exhibits phase varia-
tion [51]. Binding sites for S fimbriae are located on epithelial cells of the proximal and distal 
tubules, collecting ducts and glomerulus [55]. In humans, S-fimbriated E. coli strains are more 
closely associated with meningitis and bacteremia than with UTI [56]. They could therefore be 
important in the movement of the organism from the urinary tract to the blood stream. Few 
studies have been carried out on the role played by these two types of fimbriae in UTI patho-
genesis. FIC fimbriae are expressed by about 14% of UPEC and 7% of E. coli fecal isolates [53].
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7. Iron acquisition systems for UPEC
Bacteria and the host compete for available iron, which is needed for oxygen transport and 
storage, DNA synthesis, electron transport, and metabolism of peroxides [57, 58]. Pathogenic 
bacteria, including UPEC, have devised ways of accessing iron by producing siderophore-
mediated iron transport systems. UPEC exhibit multiple mechanisms for extracting iron from 
the host, mainly siderophore-siderophore receptor systems, but also heme uptake [59–62]. 
Siderophores, which are secreted low molecular weight molecules, have a high affinity for 
ferric (Fe3+) iron, which is insoluble as a free cation. UPEC retrieve iron-bound siderophores 
through receptors that facilitate the transportation of siderophore-iron complexes through the 
bacterial membrane and into the cytosol where the iron is concentrated and utilized. While all 
E. coli can produce the siderophore enterobactin, production of alternative siderophores has 
been shown to increase virulence of strains causing bacteremia [10].
Several enterobacteria contain a gene cluster called the high pathogenicity island (HPI), 
which encodes proteins for biosynthesis of the yersiniabactin siderophore and its uptake 
 system [63, 64]. The HPI is widespread among members of the Enterobacteriaceae family, and 
is essential for virulence in Yersinia and certain pathotypes of E. coli [63]. One of the important 
genes residing on the HPI is fyuA encoding the 71 kDa outer membrane protein FyuA (ferric 
siderophore uptake), which act as a receptor for Fe-yersiniabactin uptake [65]. FyuA, which 
was first described in Yersinia species, is associated with virulence in many members of the 
Enterobacteriaceae family [65]. Studies by Hancock and Klemm have confirmed that the ferric 
yersiniabactin receptor (FyuA) is required by UPEC for efficient biofilm formation [66].
Aerobactin is another important hydroxamate siderophore synthesized from the condensa-
tion of two lysine and one citrate molecules. In UPEC, the aerobactin system is encoded by a 
five-gene operon with four genes encoding the enzymes needed for aerobactin synthesis and 
a fifth encoding the outer membrane receptor protein [67, 68]. The synthesis genes are desig-
nated iuc, for iron uptake and chelation and the receptor gene is iut, for iron uptake and trans-
port [69]. Successive steps in the biosynthesis of aerobactin are catalyzed by the iuc genes and 
involve hydroxylation of lysine and acetylation of the hydroxyl group to form hydroxamic 
acid molecules which react with citrate to form aerobactin [69].
Previous studies have shown that the aerobactin system and P fimbriae are commonly found 
together in UPEC isolates from patients with UTI and urosepsis [70, 71]. However, among 
urosepsis patient isolates, this association is only true for chromosomally encoded aerobactin 
[71]. An association of chromosomally encoded aerobactin with hemolysin among urosepsis 
or UTI patient isolates has also been confirmed [71]. These observations suggest that the asso-
ciation of aerobactin with other VFs differs between plasmid and chromosomal aerobactin. 
Plasmids carrying the aerobactin region sometimes also carry antimicrobial resistance genes 
[71–73]. The aerobactin system is found more commonly among UPEC strains from patients 
with pyelonephritis (73%), cystitis (49%), or bacteremia (58%) than among ASB patient 
 isolates (38%) or fecal strains (41%), which suggest that aerobactin contributes to virulence 
both within and outside of the urinary tract. The association of aerobactin with more serious 
forms of UTI is seen specifically in infants, girls, and women [26, 9].
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Finally, UPEC produce salmochelins in order to access iron during invasion of the host. The 
salmochelin siderophore system, so named because it was first shown to be characteristic of 
Salmonella strains [74], is also present in UPEC. This siderophore system is encoded by iroA 
gene cluster, which is made up of five genes, iroB, iroC, iroD, iroE, and iroN. iroN gene encodes 
an outer membrane siderophore receptor which transports different catechol siderophores, 
including N-(2,3-dihydroxybenzoy)-L-serine and enterochelin. iroB encodes a glucosyltrans-
ferase that glucosylates enterobactin, iroC encodes an ABC transporter required for transport 
of salmochelins, whilst iroD and iroE encode a cytoplasmic esterase, and a periplasmic hydro-
lase, respectively [75]. The salmochelin receptor iroN may play a dual role as an iron uptake 
receptor as well as an internalization factor [10]. Using a neonatal rat model, it was shown 
that iroN plays a major role during the bacteremic step of the disease [76]. These findings sug-
gest that iroN is associated with increased virulence. Studies by Bauer et al. showed that iroN 
occurred 2.1–4 times more frequently in UTI isolates than in rectal isolates [77].
8. Toxins produced by UPEC
Most hemolytic UPEC strains secrete a heat-labile cytolytic protein toxin known as alpha 
hemolysin [78], which is encoded by a polycistronic operon, consisting of four genes arranged 
in the order of hly-CADB [79]. The product of hlyC is important in the activation of the hemo-
lytic toxin, which is the product of the hlyA gene. The gene products of hlyB and hlyD together 
with TolC are involved in secretion of the hemolysin through the bacterial cell wall [80]. The 
hemolysin determinants are located on the bacterial chromosome in human isolates of E. coli, 
in contrast to the plasmid location among animal strains [32].
Alpha hemolysin lyses red cells of all mammals and even of fish [81], and is toxic to host cells 
resulting in inflammation, tissue injury, and impaired host defenses. Hemolysin stimulates 
super-oxide anion and hydrogen peroxide release from and oxygen consumption by renal 
tubular cells, including histamine release from mast cells and basophils [82, 83]. Hemolytic 
uropathogenic strains almost always also express P fimbriae [84]. Hemolysin production is 
found most commonly in UPEC strains from patients with pyelonephritis (49%), followed by 
cystitis isolates and ASB [85]. These data demonstrate an association of hemolysin production 
with invasive uropathogenic strains. UPEC strains that produce increased amounts of alpha 
hemolysin are also more resistant to the complement action of human serum when compared 
to strains that are nonhemolytic or produce reduced amounts of hemolysin [81].
UPEC also produce a toxin referred to as cytotoxic necrotising factor type 1 (CNF-1). CNF-1 
is a chromosomally encoded UPEC toxin that catalyzes the glutamine deamination of the 
small GTPases RhoA, Rac, and Cdc 42 [86], leading to the disturbance of numerous  eukaryotic 
 cellular functions including formation of actin stress fibers, lamellipodia, filopodia, and modu-
lation of inflammatory signaling pathways [87, 88].
Yamamoto et al. showed that 61% of UTI isolates and 38% of bacteremia isolates produced 
CNF-1 as opposed to only 10% of commensal fecal isolates [89]. Of these isolates, approximately 
98% that produced CNF-1 also produced hemolysin. Studies by Mitsumori et al. showed a 
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CNF-1 prevalence of 64% among UPEC isolates from prostatitis and 36% from pyelonephritis. 
These results suggest that CNF-1 is associated with increased virulence in UTI pathogenesis. 
CNF-1 production may also increase the inflammatory response of the host [90]. Specifically, 
Elliott et al. reported that CNF-1 evokes edema and necrosis and is associated with inflamma-
tion in the intestines of rabbits in a diarrhea model of infection [90]. Human neutrophils have 
been observed to be less effective at killing CNF-1 positive, than CNF-1 negative bacteria.
9. Protectins
UPEC also express outer membrane proteins, such as traT and Iss, which may enhance serum 
resistance through avoidance of complement killing [26]. Bacteria are killed by normal human 
serum through the lytic activity of the complement system [91]. The alternative pathway is 
activated by bacteria in the absence of specific antibody and plays a more important role in 
serum killing than the classic pathway [92]. Resistance of E. coli to killing by serum results 
from the individual or combined effects of capsular polysaccharide, O-polysaccharide side 
chains, and surface proteins [93].
Although the K1 capsule is important in certain strains, other mechanisms appear to be more 
significant determinants of serum resistance in some populations of E. coli isolates. On the 
whole, smooth strains are more serum resistant than rough strains [94] and the degree of 
serum resistance is proportional to the amount of lipopolysaccharide (O antigen) the strain 
contains [95]. Serum-resistant strains are usually more nephropathogenic than comparable 
serum-sensitive strains in a variety of models of UTI [96, 97] even though these resistant 
strains may not be associated with increased lethality [96].
9.1. Outer membrane protease T
Outer membrane protease T (OmpT) of E. coli is a surface membrane serine protease and is 
the prototypical member of the omptin family of Gram-negative bacteria [98]. OmpT is an 
enzyme that catalyzes the activation of plasminogen to plasmin [99, 100], a function that is 
physiologically relevant for the virulence of Yersinia pestis and for clinical E. coli isolates [101, 
102]. OmpT also plays a role in virulence by cleavage of protamine and other cation pep-
tides with antibiotic activity [103, 104]. Studies by Hui et al. indicated that OmpT promotes 
E. coli persistence in the urinary tract by interfering with the antimicrobial activity of urinary 
 cationic peptides [100].
9.2. Uropathogenic specific protein
Uropathogenic specific protein (Usp) in E. coli, which was discovered by chance, is encoded 
by usp located on PAIs [105]. Usp, which is homologous to the Vibrio cholerae zonula occludens 
toxin gene [106], is significantly more prevalent among UPEC isolates than fecal E. coli 
 isolates from healthy individuals. Several studies have shown various roles for Usp in UTI 
 pathogenesis in different UTI syndromes and patient groups. Studies by Rijavec et al. showed 
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a strong association between Usp and bacteremia of urinary tract origin, suggesting that Usp 
is important in the migration of UPEC from the urogenital tract to the blood stream [107]. 
Other studies have shown comparable prevalences of Usp in cystitis, pyelonephritis, and 
prostatitis isolates [108]. Furthermore, Usp has (frequently) been associated with all common 
 serotypes of UPEC [109].
10. Biofilm production by UPEC
Biofilm production by E. coli is an important VF which may also protect bacteria from antibi-
otic action and so contribute to resistance [110–113]. Recent studies have shown that biofilm 
production in E. coli, mediated by co-expression of curli and cellulose, supports long-term 
survival of UPEC in the urinary tract by surrounding the organism with an inert, hydro-
phobic extracellular matrix [110, 113, 114]. Most studies of biofilm formation in UTI have 
addressed its role in recurrences.
Curli belong to a class of fibers known as amyloids and are involved in adhesion to surfaces, 
cell aggregation and, finally, biofilm development. Curli fibers are encoded in the curling 
subunit gene (csg) gene cluster, made up of two differently transcribed operons. One operon 
codes for csgB, csgA, and csgC, and the other one for csgD, csgE, and csgG [115]. Expression 
of both curli operons is important for curli fiber assembly. Curli fibers are also essential for 
internalization of bacteria during an infection [30].
Co-expression of curli and cellulose tends to decrease in prevalence from more severe to 
less severe UTI, then to commensal isolates, suggesting that biofilm may facilitate progres-
sion from the lower to upper urinary tract [110]. Furthermore, co-expression of both biofilm 
 components is associated with a high prevalence of individual VF genes, high VF scores, 
and phylogenetic group B2, consistent with heightened urovirulence of such strains. Notably, 
there may be an interaction between classic VFs and biofilm formation. For example, in one 
study, all isolates that co-expressed both biofilm components also harbored fyuA, imply-
ing that iron uptake via the yersiniabactin system may play a significant role in biofilm 
growth [64]. Additionally, recent studies have shown that the biofilm components, curli fim-
briae and cellulose, also play important roles in adhesion, invasion, and long-term survival of 
UPEC within the host  urinary tract [110, 111].
11. Phylogenetic group and VF distribution among patient groups and 
clinical syndromes
E. coli is commonly classified into four main phylogenetic groups namely A, B1, B2, and D [116] 
as defined by multilocus enzyme electrophoresis and multilocus sequence typing [117]. Several 
studies have shown that E. coli pathogenic strains from extraintestinal infections mostly derive 
from group B2, and to a less extent group D [21, 118, 119]. Most studies quote prevalence rates 
around 63–65% for group B2 in pathogenic strains, and 10–15% for group D [21]. Commensal 
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E. coli are mainly associated with phylogenetic groups A or B1, and are mainly devoid of 
virulence determinants [118, 120, 121]. The overlapping associations of VFs and phylogeny 
with clinical virulence makes it difficult to understand which directly determines virulence. 
However, some studies in children showed that pyelonephritis isolates more often belonged to 
group B2, contained on average higher prevalences of individual VF genes, and consequently 
had higher VF scores than did cystitis or fecal isolates, suggesting that both VF repertoire and 
phylogenetic background play important roles in UTI pathogenesis.
UTI syndrome-specific differences among E. coli clinical and fecal isolates from men are 
 consistent with findings from women, which have shown a gradient of virulence from E. coli 
strains causing more invasive UTI syndromes, such as pyelonephritis and febrile UTI, through 
those causing cystitis, to fecal strains [9, 122]. However, men are less likely than women or 
girls, to develop cystitis due to low-virulence strains, which is consistent with a previous 
observation that isolates from men with febrile UTI appeared relatively virulent, even in the 
presence of host compromise [122].
In most patient groups, pyelonephritis isolates tend to exhibit the highest prevalences of many 
individual VFs, have the highest VF scores, and are the most likely to belong to phylogenetic 
group B2, ST131, and a UTI-associated O type. The reported higher prevalence of pap operon 
genes (encoding P fimbriae) in pyelonephritis than cystitis isolates correlates with increased 
tropism for the kidney of P fimbriated strains [121, 123]. papGII has been shown, experi-
mentally, to contribute to pathogenesis of pyelonephritis [124, 125], and OmpT is strongly 
associated with febrile UTI in men [122, 126]. However, it is not clear whether these VFs act 
individually or in concert with other known or unknown VFs in causing pyelonephritis.
In men and women, although cystitis and pyelonephritis isolates differ in inferred  molecular 
virulence, phylogenetic group distribution is similar between the two clinical syndromes. 
However, within each phylogenetic group, VF scores exhibit a gradient across source groups 
(fecal < cystitis < pyelonephritis), suggesting the presence of different virulence strata within 
each phylogenetic group, with more virulent strains selectively causing pyelonephritis and 
less virulent strains being associated with cystitis and fecal isolates in that order. This  suggests 
that VF repertoire is as, or more, important than phylogenetic background for  predicting 
pathogenic behavior in UPEC [122, 127].
Although cystitis and pyelonephritis isolates differ significantly in inferred virulence in vari-
ous patient groups, no single VF profile is unique to any clinical syndrome or patient group, 
implying that UTI pathogenesis is multiply determined, as suggested by several previous 
studies [122, 128]. Thus, intervention strategies based on VF genes might have to involve 
multiple targets, which would offer the extra advantage of protection against a wide range 
of UTI syndromes.
12. Transmission of VFs
The genes encoding specific UPEC VFs can be exclusively chromosomal (e.g., pap and hly); 
exclusively or principally plasmid-associated (e.g., iss and traT); or can occur in either  location 
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(e.g., the aerobactin operon and afa/drab). Plasmid-borne VFs have an obvious vehicle for 
horizontal transmission among E. coli lineages. Such VFs tend to be distributed more broadly 
but more sporadically within the species than are chromosomal VFs [129]. Studies have dem-
onstrated that certain VFs commonly occur together, in a way that suggests co-selection or 
direct genetic linkage [130, 131]. Direct genetic linkage of VFs has been shown on PAIs and 
plasmids [132–134].
13. Antimicrobial drugs and uropathogenic Escherichia coli
Managing UTI caused by UPEC has become challenging over the years due to increasing resis-
tance to the commonly used antibiotics [135–139], which poses a great threat to future capacity 
to treat UTI caused by UPEC. Although TMP-SMX has traditionally been used as a first-line 
treatment for UTI [140], there are reports of increased resistance to this antibiotic, which in 
some countries is in the range 15–20% [137]. Many UPEC strains resistant to TMP-SMZ are also 
resistant to amoxicillin and cephalexin. Nitrofurantoin remains highly effective against UPEC, 
but is mainly used for cystitis treatment due to its inability to attain sufficient serum levels to 
treat invasive or systemic infections [137], and all have excellent bioavailability and achieve 
high urinary concentrations. However, increased FQ use has resulted in a rise in the prevalence 
of resistance, and FQ-resistant E. coli has become a major problem in several countries [141].
14. Relationship between antibiotic resistance and virulence or 
phylogenetic background in UPEC
Previous studies show that in E. coli isolates from patients with urosepsis, resistance to anti-
microbial agents such as ampicillin, sulfonamides, tetracycline, chloramphenicol, and strep-
tomycin is negatively associated with virulence and a phylogenetic group B2, but positively 
associated with host compromise (immune deficiency, diabetes, and other urinary anatomical 
abnormalities) [26]. There is a similar negative association between FQ resistance and VFs and 
group B2 [142–144]. This suggests that, resistance may provide a greater fitness advantage to 
E. coli than traditional VFs or a group B2 background, allowing them to cause infections in 
compromised hosts with weakened defenses who are frequently exposed to antibiotics.
15. E. coli sequence type 131 (ST131)
Determining the clonal types of UPEC is crucial for understanding the role of clonal spread 
to emerging antimicrobial resistance, which is important for defining and interrupting trans-
mission pathways. Multidrug-resistant E. coli sequence type 131 (ST131) has emerged over 
the past decade as a globally disseminated cause of extraintestinal infections in humans and 
 animals [145–147]. The recent emergence of this clone has coincided with an increase in antibi-
otic resistance among E. coli generally, suggesting a contributing role for ST131 in resistance.
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In contrast to traditional antimicrobial resistant E. coli, which mostly derive from low virulence 
phylogenetic groups A and B1, ST131 derives exclusively from phylogenetic group B2, which 
is traditionally known to be enriched for VF genes. This, plus limited experimental evidence of 
virulence and several case reports of unusually severe or fatal extraintestinal infections due to 
ST131, suggests that the emergence of ST131 may be due to a high virulence potential (in addi-
tion to antibiotic resistance) compared with other E. coli types. However, despite this, some 
studies have reported absence of traits commonly associated with B2 phylogeny, particularly 
adhesins (e.g., P, S, and FIC fimbriae) and toxins (e.g., hemolysin and cnf1).
Most ST131 clinical isolates are FQ resistant, and many are also co-resistant to aminoglycosides 
and/or trimethoprim-sulfamethoxazole (TMP-SMZ). A minority produces extended-spectrum 
beta-lactamases (ESBLs) that confer resistance to extended-spectrum cephalosporins. E. coli 
clonal group ST131 may be associated with other beta-lactamases but some isolates are cephalo-
sporin susceptible [148, 149].
Despite limited epidemiological evidence of increased virulence of ST131, a recent study 
revealed that ST131 exhibits a marked prevalence gradient across source groups, from pyelo-
nephritis to cystitis isolates, and finally to fecal isolates [126]. This is consistent with increased 
urovirulence, and provides epidemiological evidence of increased virulence for ST131, which 
has been presumed but without evidence from experimental animal models [8, 150]. The anti-
biotic resistance advantage, in combination with the possible presence of enhanced virulence, 
could explain the recent worldwide emergence of ST131. The increasing prevalence of ESBL-
producing E. coli has been associated with the emergence of CTX-M-ST131 pandemic clonal 
group [151]. Available evidence supports that ST131 is an important contributor to the spread 
of ESBLs among reproductive-age women in some regions, albeit limited research in many 
parts worldwide [141, 152].
Four VF genes (iutA, ompT, usp, and traT) are associated with ST131 isolates, and so could 
represent potential targets for vaccines or other interventions, particularly if a functional role 
in virulence or dissemination can be demonstrated for them. Most of the ST131 isolates (85%) 
are of the O25b variant, and the remainder are type O16 [153, 154].
Resistance of ST131 to extended-spectrum cephalosporins is often due to production of 
ESBLs. The initial descriptions of ST131 emphasized its association with CTX-M-15, but 
subsequent studies have shown that it is more commonly ESBL-negative but FQ-resistant 
[154–156]. Previous studies in Australia and Japan showed that ST131-O25b, ST131-O16, and 
group D-ST405 clonal groups contribute to the spread of ESBL-producing E. coli [151, 152]. 
The dominant ESBL, in E. coli, globally and in Australia [157] is CTX-M-15, which is frequently 
encoded on plasmids carried by the ST131 pandemic clonal group.
16. Conclusions
A wide range of UPEC VFs have been established epidemiologically or experimentally 
(in vivo) as being important in UTI pathogenesis. No single VF profile has been proven to 
be important in causing any particular UTI syndrome. Indeed, studies have suggested that 
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UTI pathogenesis is multiply determined. Thus, intervention strategies based on VF genes 
might have to involve multiple targets, which would offer the extra advantage of protection 
against a wide range of UTI syndromes. This observation, which is in agreement with previ-
ous studies, provides evidence that VF repertoire is as, or more, important than phylogenetic 
background for predicting pathogenic behavior in UPEC.
The prevalence of antibiotic resistance among human urine E. coli isolates has risen substan-
tially in recent years, especially to first line agents such as fluoroquinolones and trimethoprim-
sulphamethoxazole. Furthermore, multidrug-resistant E. coli ST131 has shown rapid global 
dissemination among humans and animals, which has coincided with the general increase in 
resistance among E. coli clinical isolates. A better understanding of the microbiological basis 
for the emergence of UPEC antibiotic resistance is necessary for guiding efforts aimed at inter-
rupting this process. Further studies on ST131 are clearly needed to explain its impressive 
emergence so that control measures can be devised and implemented.
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